Citations

Clear

9383 citation(s) found for "Thomas, PS".

Functional Outcomes in Bipolar Disorder: Cross-Cohort Analyses from the Global Bipolar Cohort
Yocum, *Anastasia K., Fullerton, *Janice M., Ashton, Melanie M., Overs, Browyn J., Diaz‐Byrd, Claudia , Albarracín-García, Lucía , Alda, Martin, Alexander, Nina , Altimus, Cara M. , Altınbaş, Kürşat, Andreassen, Ole A., Aubin, V. , Baca-García, Enrique, Baune, Bernhard T., Belzeaux, Raoul , Benavente-López, Sergio, Bengesser, Susanne A., Berk, Michael, Biernacka, Joanna, Blumberg, Hilary P., Burdick, Katherine E., Carpiniello, Bernardo, Chang, Chiao-Erh , Chen, Wen Yin, Clark, Scott R., Cleare, Anthony J., Contu, Martina , Dafnas, Konstantinos , Dannlowski, Udo, Dikeos, Dimitris, Dodd, Seetal, Dols, Annemieke, Dubertret, C, Etain, Bruno, Eyler, Lisa T., Fatjó‐Vilas, Mar , Ferentinos, Panagiotis, Ferguson, B. , Fernández, Ana L., Flinkenflügel, Kira, Forester, Brent P. , Fries, Gabriel R., Frye, Mark A., Fuentes-Claramonte, Paola, Gard, Sébastien, Gergel, Tania, Godin, O, Green, MJ, Haffen, E, Hahn, Tim, Havard, Alys, Jamalabadi, Hamidreza, Jansen, Andreas, Jones, I, Jones, Lisa A., Kelsoe, John R., Kircher, Tilo, Klaus, Federica, Kulkarni, Jayashri , Kupka, Ralph W., Leboyer, M, Lenger, Melanie , McElroy, Susan L., Machado-Vieira, Rodrigo, Manchia, Mirko, Martin, Nicolas G., Mata-Iturralde, Laura, Meinert, Susanne, Mitchell, Philip B., Mitra, Romita, Mohebbi, Mohammadreza , Mwangi, Benson, Nenadić, Igor, Nierenberg, Andrew A., Nunes, Abraham, Olié, E, O'Donovan, Clair, Orhan, Melis M., Passerieux, Christine, Perich, Tania, Peters, Amy T. , Petite, Joanne, Pham, Dániel , Pinna, M A, Platzer, Martina, Polosan, Mircea , Pomarol-Clotet, Edith, Porta-Casteràs, Daniel, Potter, Julia R., Quidé, Yann, Regeer, Eline J. , Rheenen, Tamsyn E. Van, Roberts, Gloria, Rodríguez-Cano, Elena, Rossell, Susan L., Sajatovic, Martha, Salvador, Raymond, Samalin, Ludovic, Sánchez-Alonso, Sergio, Sarró, Salvador , Schubert, Klaus O., Schwan, R, Scott, Katie , Shanahan, Megan, Soares, Jair C., Solé, Brisa, Stein, Dan J., Stein, Frederike, Strakowski, Stephen M., Straube, Benjamin, Strawbridge, Rebecca, Sullivan, Patrick F., Teutenberg, Lea, Thiel, Katharina , Thomas-Odenthal, Florian, Toma, Claudio, Usemann, Paula L., Vieta, Eduard, Vilella, Elisabet, Viswanath, Biju, Williams, Lana J., Wu, Mon-Ju, Yatham, Lakshmi N., Young, Allan H., McInnis, Melvin G., Almeida, Jorge, Bora, Emre, Cannon, Dara M., Chang, Yun-Hsuan, Chaumette, Boris, Chen, Jun, Ching, Christopher, Escamilla, Michael , Forstner, Andreas J., Goghari, Vina M. , He, Qin, Huang, Hailiang, Juruena, Mario F.; id_orcid 0000-0001-8558-3396, Kasyanov, Evgeny D., Koenig, B., Kovács, Zoltán , Kulkarni, Alok, Lee, Heon-Jeong, Lee, Jimmy, Liao, Duanping , LICHT, RASMUS W., Melle, Ingrid, Nicolini, Humberto, Okawa-Belizario, Gabriel, Prieto, Miguel L. , Raventós, Henriette , Ardestani, Seyed M. Samimi, Saunders, Erika F., Savitz, Jonathan, Schulze, Thomas G., Serretti, Alessandro, Simhandl, Christian , Straszek, Sune, SOUSA, RAFAEL TEIXEIRA DE , Thompson, Paul M., Tondo, Leonardo, Tourjman, S. Valérie, Zandi, Peter, Quidé, Yann , Overs, Bronwyn J. , Quidé, Yann , Sarró, Salvador , Yocum, Anastasia K. , Fullerton, Janice M. , Ashton, Melanie M. , Alda, Martin , Alonso-Lana, Sílvia , Altınbaş, Kürşat , Andreassen, Ole A , Antoniou, Anastasia , Baca‐García, Enrique , Baune, Bernhard T., López, Sergio Benavente , Berk, Michael , Beunders, Alexandra J.M. , Blumberg, Hilary P. , Brosch, Katharina , Burdick, Katherine E. , Callahan, Tiffany J , Cano, Marta , Cardoner, Narcı́s , Carpiniello, Bernardo , Chen, I‐Ming , Clark, Scott , Cleare, Anthony J. , Dalkner, Nina , Dannlowski, Udo , Dikeos, Dimitris, Dodd, Seetal , Dols, Annemiek , Dubertret, Caroline , Étain, Bruno , Eyler, Lisa T. , Fellendorf, Frederike T. , Flinkenflügel, Kira , Di Florio, Arianna , Fries, Gabriel R. , Frye, Mark A. , Fuentes‐Claramonte, Paola , Gergel, Tania , Godin, Ophélia , Gordon‐Smith, Katherine , Haffen, Emmanuel , Hahn, Tim , Hartmann, Simon , Havard, Alys , Hickie, Ian Bernard , Jamalabadi, Hamidreza , Jansen, Andreas , Kelsoe, John R , Kircher, Tilo , Klaus, Federica , Kuo, Po‐Hsiu , Kupka, Ralph , Lagerberg, Trine Vik , Leboyer, Marion , Lind, Penelope A. , McElroy, Susan L. , Machado‐Vieira, Rodrigo , Manchia, Mirko , Martínez‐Arán, Anabel , Medland, Sarah E. , Meinert, Susanne L. , Miklowitz, David J. , Millett, Caitlin E. , Mitchell, Philip B , Muntané, Gerard , Mwangi, Benson , Nenadić, Igor , Nierenberg, Andrew A. , Nurnberger, John I , Olié, Émilie , Orhan, Melis , Paribello, Pasquale , Passerieux, Christine , Perich, Tania , Pisanu, Claudia , Pomarol‐Clotet, Edith , Casteràs, Daniel Porta , Potter, Julia R, Reininghaus, Eva , Van Rheenen, Tamsyn , Ringin, Elysha , Ritter, Philipp , Roberts, Gloria, Rodríguez‐Cano, Elena , Rossell, Susan Lee , Sajatovic, Martha , Samalin, Ludovic , Scaini, Giselli , Schofield, Peter R. , Schouws, Sigfried N. T. M. , Schubert, Klaus Oliver , Schwan, Raymund , Shanahan, Megan, Siskind, Dan , Soares, Jair C. , Squassina, Alessio , Stein, Dan J. , Stein, Frederike , Strakowski, Stephen M. , Straube, Benjamin , Strawbridge, Rebecca , Stuart, Amanda L. , Teutenberg, Lea , Thomas‐Odenthal, Florian , Toma, Claudio , Torres, Ivan J. , Tsapekos, Dimosthenis , Ueland, Torill , Usemann, Paula L , Vieta, Eduard , Vilella, Elisabet , Viswanath, Biju , Winter, Alexandra , Wootton, Olivia , Wrobel, Anna L , Yatham, Lakshmi N. , Young, Allan H. , McInnis, Melvin G. , Bora, Emre , Cannon, Dara M. , Chaumette, Boris , Forstner, Andreas J. , Grigoroiu‐Serbânescu, Maria , He, Qin , Juruena, Mário F. , Kasyanov, Evgeny Dmitrievich , Koenig, Barbara, Lafer, Beny , Vernal, Ditte Lammers , Lee, Heon‐Jeong , McMahon, Francis J. , McQuillin, Andrew , Melle, Ingrid , Najand, Babak , Nicolini, Humberto , Belizário, Gabriel Okawa , Redlich, Ronny , Ardestani, Seyed Mehdi Samimi , Saunders, Erika F.H. , Savitz, Jonathan B. , Schulze, Thomas , Serretti, Alessandro , Σκώκου, Μαρία , Straszek, Sune Puggaard Vogt , Sousa, Rafael Teixeira de, Thompson, Paul M. , Tondo, Leonardo , Xiong, Ashley

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9390347/v1 Get It

Abstract Background The Global Bipolar Cohort (GBC) was established to identify existing bipolar disorder (BD) cohorts worldwide and foster collaborations focused on descriptive and analytic outcomes relevant to BD. A distributed analytic framework has been implemented to engage multiple sites without the need for central data pooling. This report describes the GBC endeavor and global functional impairment patterns. Cross-cohort comparisons of functional correlates are limited by heterogeneous measures and data-sharing constraints. Large, culturally diverse comparisons are needed to distinguish broadly reproducible correlates from cohort-specific effects. Participating sites completed a 28-item descriptive survey covering diagnostic methods, cognition, genetics, treatment, functioning, and follow-up strategies. We implemented a harmonized local logistic regression model of dichotomized functional outcome and shared summary statistics only. Results We identified 69 cohorts across five continents. Thirty-seven cohorts contributed functional outcome analyses from 17,130 participants. Outcome measures included clinician-rated disability scales and social indicators such as employment and marital status. The proportion classified with poor functioning ranged from 16% to 77% (mean 50%). In 32 of 37 cohorts, the overall regression model significantly explained variance in functioning. Current depressive symptoms were the most robust and reproducible correlate of poor functional outcome: they were assessed in 29 cohorts, significant in 22 (75.8%), ranked among the top three correlates in 22, and were the top-ranked correlates in 19. Associations between depressive burden and poor functioning were observed across clinician-rated disability scales and work or social indicators, and across geographically diverse cohorts. Comorbid substance use disorder and medication-related variables were associated with poorer functioning in subsets of cohorts, whereas sex, ancestry, bipolar subtype, psychosis history, and premorbid IQ showed weak or inconsistent associations. Cognitive measures, available in a minority of regression models, showed modest and non-uniform effects. Conclusions Across heterogeneous international cohorts, current depressive symptom burden emerged as the most consistent correlate of poor functioning in bipolar disorder. These findings replicate earlier multisite work at a larger scale, show that protocol-based distributed analyses can identify reproducible clinical signals without sharing individual-level data, and support prioritizing detection and treatment of depressive symptoms when aiming to improve real-world functioning. Future work should expand longitudinal harmonization and representation of under-studied populations.
Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease
Nishimura, Yoshito, Estevez, Maria Santiago, ASAD, HAKEEM , Habermann, T. M., Habermann, Thomas M. , Habermann, Thomas , Nishimura, Yoshito , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | May 9, 2026 | Volume: 101 | Issue: 8 | Pages: 2033-2037

10.1002/ajh.70352 | PMID 42104162 Get It

0784 Longitudinal Outcomes and Predictors of Phenoconversion in the Mayo Clinic Isolated REM Sleep Behavior Disorder Registry
Li, Alan, Tripp, Ellery, Issa, Diana, Cesarone, Olivia , Finstuen, Thomas, Jagielski, Jack, Boeve, Bradley, Junna, Mithri, Lipford, Melissa, Tippmann‐Peikert, Maja, Carvalho, Diego, Silber, Michael , McCarter, SJ, LOUIS, ERIK ST., Tripp, Ellery R. , Finstuen, Thomas, Jagielski, Jack T. , Boeve, Bradley, Junna, Mithri R.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A351-A351

10.1093/sleep/zsag091.0783 Get It

Abstract Introduction Isolated REM sleep behavior disorder (iRBD) is characterized by loss of normal REM sleep atonia and dream enactment behavior. iRBD is strongly associated with α-synucleinopathies and risk for developing Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), yet phenoconversion risk for long-term outcomes of younger women and men remains undefined. We aimed to ascertain longitudinal outcomes and phenoconversion risk in the Mayo Clinic iRBD cohort. Methods Eighty-nine of 165 registry participants with at least one-year follow-up were included. Retrospective chart review attained baseline demographics, age at presentation, baseline Timed Up and Go (TUG) and Montreal Cognitive Assessment (MoCA) scores, and phenoconversion status (iRBD, PD, DLB, mild cognitive impairment [MCI], MSA, or other). Kaplan–Meier survival analysis and Cox proportional hazards modeling were analyzed with alpha at p < 0.05. Results 68 men and 21 women had a mean age of 63 years at polysomnographic diagnosis. At follow-up, 64 (71.9%) remained iRBD; 7 (7.9%) developed PD, 11 (12.4%) developed DLB, 3 (3.4%) developed MCI, 1 (1.1%) developed MSA, and 3 (3.4%) developed another dementia. Abnormal TUG (>12 seconds) occurred in 5.9% and abnormal MoCA (< 24) in 23.3%. Phenoconversion rates were similar in women and men (p = 0.44). Older age at PSG predicted phenoconversion, corresponding to a two-fold increase in risk with each 10-year increase (HR 2.00, 95% CI 1.15–3.52). Neither abnormal TUG nor MoCA predicted conversion. Cumulative phenoconversion was approximately 1% at 1 year, 7% at 3 years, 10% at 5 years, 30% at 10 years, 34% at 12 years, and 49% at 15 years. Mean and median time to phenoconversion was 7 years (range, 1-18 years). Conclusion We found that iRBD phenoconversion rates were lower than historically reported. Only age at presentation predicted phenoconversion, with risk doubling per decade. At 12 years, cumulative phenoconversion rate was approximately 34%. Support (if any)
0755 Patient-Reported Improvement in Hypersomnolence Measures in Participants with Narcolepsy Taking >9 Gram Dosage of Low-Sodium Oxybate in the DUET Study
BOGAN, RICHARD, Ruoff, Chad, Plante, David, Nichols, Deborah, Steininger, Teresa, Dai, Jing , Measey, Thomas, Whalen, Marisa, Cairns, A., Schneider, Logan, Simmons, Jerald, Schneider, Logan , Ruoff, Chad , Ruoff, Chad M , Bogan, Richard , Whalen, Marisa, Cairns, Alyssa , Simmons, Jerald

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A337-A337

10.1093/sleep/zsag091.0754 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment; NCT05875974) was the first study to evaluate effectiveness/safety of low-sodium oxybate (LXB; Xywav®) >9 g/night (outside the recommended range: 6–9 g/night). This analysis evaluated changes in patient-reported hypersomnolence measures in participants with narcolepsy taking LXB >9 g/night compared with LXB 9 g/night. Methods DUET was a phase 4, prospective, open-label study with screening, 8-day LXB 9 g/night (9g-baseline), titration/optimization, stable-dose, and 8-day end-of-treatment (EOT) optimized LXB >9 g/night (up to 12g; >9g-EOT) periods. Patient-reported measures included Epworth Sleepiness Scale (ESS), electronic sleep diaries (completed daily during 9g-baseline and >9g-EOT; subjective total sleep time [TST], number of awakenings, sleep efficiency [TST divided by time in bed], sleep quality [5-point scale; “very good” to “very poor”], and how rested/refreshed the participant felt upon awakening [5-point scale; “very well” to “not at all”]), Karolinska Sleepiness Scale (KSS; administered 90 minutes post-polysomnography awakening at 9g-baseline and >9g-EOT), and Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10). LSM differences (95% CI) from 9g-baseline to >9g-EOT (nominal P-values) were 9g-baseline-adjusted. Results Forty-eight participants took LXB >9g (mean±SD age: 39.2±10.9 years; 62.5% female). Total stable-dose LXB (mean±SD) was 11.1±1.0 g/night (n=45). From 9g-baseline to >9g-EOT, ESS scores improved (LSM [95% CI]: –3.1 [–4.2, –1.9]; P< 0.0001; n=44), nocturnal TST increased (0.3h [0.1, 0.4]; P=0.0163; n=26), sleep efficiency increased (3.8% [1.7, 5.9]; P=0.0011; n=26), and number of awakenings remained stable (–0.2 [–0.7, 0.3]; P=0.3959; n=26). Percentage of participants rating sleep quality as “very good”/”good” increased from 26.9% (9g-baseline) to 61.5% (>9g-EOT), as did rested sleep (“very well”/”well”/”somewhat” rested) from 57.7% to 69.2%, respectively. From 9g-baseline to >9g-EOT, KSS scores decreased (–0.9 [–1.4, –0.4]; P=0.0004; n=39); FOSQ-10 scores also increased (1.3 [0.5, 2.0]; P=0.0014; n=40). Of 48 participants, 36 (75.0%) experienced ≥1 TEAE (mostly mild/moderate and 1 serious [syncope, unrelated to treatment]). No changes in respiratory polysomnography measures were observed. Conclusion Participants with narcolepsy who optimized to LXB >9 g/night, relative to 9 g/night, reported increased sleep quality and restfulness that paralleled improvements in daytime sleepiness and daytime functioning. TEAEs were consistent with those at lower dosages. Support (if any) Jazz Pharmaceuticals
Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study)
Celda, María Peris, Little, Andrew S, Gardner, Paul, Zenonos, Georgios, Evans, J., Fernandez-Miranda, Juan, Mamelak, Adam N, Rennert, Robert C, Couldwell, William T, Zada, Gabriel, Kim, Albert H, Silverstein, Julie M, Kim, Won, Bergsneider, Marvin, Wu, Kyle C, Prevedello, Daniel M, Zwagerman, Nathan, Cheok, Stephanie , Catalino, Michael P, Kshettry, Varun R, Karsy, Michael, Gompel, Jamie J Van, Karsy, Michael , Shinya, Yuki , Palit, Sandhya R. , Peris Celda, Maria, Karsy, Michael , Little, Andrew S. , Little, A.S., Pacult, Mark A. , Gardner, P., Zenonos, G., Evans, J., Fernandez-Miranda, J., Rennert, R.C., Couldwell, WilliamT., Zada, G., Kim, A.H., J.M., Silverstein, Kim, W., Bergsneider, M., Wu, K.C., Prevedello, D.M., Zwagerman, Nathan T. , Cheok, S., Catalino, Michael P. , Kshettry, Varun R. , Van, Gompel J.J.

Mayo Clinic

Journal of Neurosurgery | May 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2025.12.jns252065 | PMID 42066361 Get It

OBJECTIVE Adamantinomatous craniopharyngioma (ACP) is a rare type of brain tumor that affects a wide age range, from children to older adults. Due to the rarity of the disease, existing studies are predominantly limited to single-center or single-surgeon experiences, often lacking statistical power and generalizability. The aim of this study was to address this gap by providing a comprehensive analysis of ACP outcomes based on a large multicenter cohort from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). METHODS This multicenter retrospective cohort study was conducted via the RAPID consortium and assessed patients with histologically confirmed ACP treated surgically between August 2000 and November 2024 at high-volume pituitary centers across the United States. RESULTS Among the 359 patients (206 male, median age at primary surgery of 47 years) included in the analysis, 76% underwent endoscopic transsphenoidal surgery and 22% underwent craniotomy. Gross-total resection was achieved in 45% and subtotal resection in 47%. Notably, 120 of 311 patients (39%) presented with preoperative hypothalamic-pituitary axis dysfunction. Following all treatments, permanent hypothyroidism was reported in 40% of patients, adrenal insufficiency in 33%, and arginine vasopressin deficiency in 19%. Of 263 patients who underwent primary surgery, radiation therapy was administered in 84 (32%). Progression-free survival (PFS) declined from 66% at 1 year to 31% at 6 years. In the multivariable analysis, independent predictors of worse PFS included subtotal resection (HR 0.22, 95% CI 0.11–0.42; p = 0.001), partial resection (HR 0.11, 95% CI 0.04–0.28, p = 0.001), larger tumor size (HR 0.77, 95% CI 0.64–0.94; p = 0.009), and tumor extension beyond the sella and suprasellar regions (HR 0.21, 95% CI 0.06–0.74; p = 0.016). Primary surgery and salvage surgery groups showed comparable PFS. CONCLUSIONS In this large multicenter cohort study, gross-total resection was achieved in fewer than half of patients and was independently associated with improved PFS. Approximately one-third of patients underwent radiation therapy after primary surgery. These findings provide robust evidence supporting the prognostic value of extent of resection and inform contemporary treatment algorithms for ACP. The high incidence of postoperative endocrinopathy underscores the need for individualized multidisciplinary long-term care. While the retrospective design is a limitation, the multicenter approach enhances the generalizability of these results.
CT Attenuation Map–Derived Body Composition Is Associated with Cardiorespiratory Fitness in Multicenter External Validation
Miller, Robert J.H. , Yi, Jirong, Shanbhag, Aakash, Feher, Attila, Miller, Edward J. , Ramirez, Giselle, Travin, Mark I. , Carvajal-Juarez, Isabel, Packard, René R S, Al-Mallah, M., Mason, Steve, Wopperer, Samuel, Buechel, R M, Rosamond, Thomas, Berman, Daniel S., Dey, Damini, Carli, Marcelo F. Di , Slomka, Piotr, Buechel, Ronny R. , Carvajal-Juarez, Isabel , Miller, Edward J , Slipczuk, Leandro , Packard, Rene R S , Al-Mallah, Mouaz H , Buechel, Ronny R , Slomka, Piotr J , Carvajal-Juarez, Isabel , Miller, Robert J H , Patel, Krishna , Ruddy, Terrence D , Einstein, Andrew Jeffrey , Feher, Attila , Liang, Joanna X., Slipczuk, Leandro , Alexanderson, Erick , Packard, René R. Sevag , Al‐Mallah, Mouaz H. , Acampa, Wanda , Knight, Stacey , Le, Viet T. , Mason, Steve, Wopperer, Samuel, Chareonthaitawee, Panithaya , Berman, Daniel S. , Dey, Damini

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.07.26352573 | PMID 42145618 Get It

ABSTRACT Aims Exercise capacity is a powerful predictor of cardiovascular risk. In patients unable to exercise, body composition analysis can potentially be used to estimate cardiorespiratory fitness. We developed a body composition “fitness” score, then validated its utility in two external populations. Methods and Results We included patients from four sites undergoing single photon emission computed tomography (SPECT) and twelve sites undergoing positron emission tomography (PET). We quantified body composition using deep learning. We evaluated associations between body composition and good exercise capacity (defined as completing ≥7 minutes on a Bruce protocol) then developed a body composition “fitness” score. We then assessed the associations of “fitness” score with exercise capacity and all-cause mortality in external populations. In total, 36471 patients were included with median age 67 (interquartile range 58 – 74). Median skeletal muscle density was higher among patients with good exercise capacity. In the external SPECT population, the body composition “fitness” score had higher prediction performance for good exercise capacity (AUC 0.771, 95% CI 0.752 – 0.789) than age (AUC 0.717, p<0.01). In the external PET population, high body composition “fitness” score was associated with lower cardiovascular death (adjusted hazard ratio 0.70, 95% CI 0.62 – 0.79, p<0.001). Conclusions We demonstrated that a comprehensive body composition “fitness” score could identify patients with good cardiorespiratory fitness. This approach transforms routinely acquired CT data into a surrogate marker of fitness which can be applied in patients undergoing PET, or other CT imaging, where exercise testing is not performed. Graphical Abstract Overview of study design. The overall population (n=36471) was split as outlined above. Body composition was analyzed from available computed tomography imaging. The distribution of body composition measures were analyzed in the combined single photon emission computed tomography (SPECT) populations. A body composition “fitness” score was derived to predict good exercise capacity in the internal population, with associations assessed in the two external testing populations.
Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia
Shrestha, Srishti , Zhu, Xiaoqian , Windham, B Gwen, Sullivan, Kevin J, Palta, Priya, Gottesman, Rebecca F, Tracy, Russell P, Jack, Clifford R, Cogswell, Petrice M, Vemuri, Prashanthi, Seshadri, Sudha, Mosley, Thomas H, Griswold, Michael E, Fornage, Myriam, Windham, B. Gwen , Sullivan, Kevin, Gottesman, Rebecca F. , Tracy, Russell P. , Jack, Clifford R. , Cogswell, Petrice M. , Vemuri, Prashanthi , Seshadri, Sudha , Mosley, Thomas H. , Griswold, Michael , Fornage, Myriam

Mayo Clinic

Alzheimer's & Dementia | May 7, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71422 | PMID 42092335 Get It

Abstract INTRODUCTION Prospective studies of blood‐based biomarkers reflecting pathogenic processes, other than Alzheimer‐specific pathologies, that contribute to dementia in diverse cohorts are lacking. METHODS We jointly fitted linear mixed‐effect models and proportional hazards models to examine associations of midlife glial fibrillary acidic protein (GFAP), chitinase‐3‐like protein 1 (YKL‐40), soluble cluster of differentiation‐14 (sCD14), neurofilament light chain (NfL), total tau (t‐tau), and ubiquitin C‐terminal hydrolase L1 (UCHL1) levels in serum (collected in 1993 to 1995) with cognitive decline and incident dementia (ascertained over 29 years through 2022) in the community‐based Atherosclerosis Risk in Communities Study. sCD14 and YKL‐40 were measured in 3082 participants and the other four biomarkers in 1766 participants. RESULTS Higher serum GFAP, YKL‐40, sCD14, and NfL were associated with faster cognitive decline and elevated dementia rate (e.g., 1 standard deviation [SD] higher log‐base2 YKL‐40 was associated with −0.11SD faster 25‐year cognitive decline (95% confidence interval [CI]: −0.15,−0.07) and 45% higher dementia hazard (hazard ratio [HR]: 1.45 [95% CI: 1.25, 1.68]). Higher t‐tau and UCHL1 were also associated with faster cognitive decline. DISCUSSION Midlife blood biomarkers reflecting glial and neuronal dysfunction and neuroinflammation are associated with early cognitive impairment.
Tumor mutational and microbial profiles of early-onset and later-onset colorectal cancers according to detailed tumor location: an international pooled analysis
Ugai, Tomotaka, Ugai, Satoko , Qu, Conghui, Toland, Amanda E., French, Amy J. , Gsur, Andrea , Chan, Andrew T., Guelpen, Bethany van, Lynch, Brigid, Um, Caroline Y., Newton, Christina, Thomas, Claire E., Buchanan, Daniel D., Drew, David, Goode, Ellen L., Aglago, Elom K., Brenner, Hermann, Figueiredo, Jane C., Huyghe, Jeroen R., Nowak, Jonathan A., Doheny, Kimberly F., Hsu, Li, Boardman, Lisa, Gunter, Marc J., Giannakis, Marios, Jenkins, Mark A., Obon-Santacana, Mereia, Hoffmeister, Michael, Song, Mingyang, Murphy, Neil, Campbell, Peter T., He, Qianchuan, Trinh, Quang M., Pai, Rish K. , Steinfelder, Robert S. , Berndt, Sonja I., Gruber, Stephen B., Gallinger, Steven, Zaidi, Syed H., Hudson, Thomas J., Moreno, Victor, Sun, Wei, Huang, Wen-Yi, Lin, Yi, Cao, Yin, Peters, Ulrike, Hullar, Meredith, Phipps, Amanda I., Ugai, Tomotaka , Chen, Yu , Qu, Conghui , Chan, Andrew T , Um, Caroline Y. , Thomas, Claire E. , Buchanan, Daniel D. , Drew, David A. , Aglago, Elom K. , Brenner, Hermann , Figueiredo, Jane C. , Huyghe, Jeroen R. , Nowak, Jonathan A. , Doheny, Kimberly F. , Gunter, Marc J. , Giannakis, Marios , Jenkins, Mark A. , Obón‐Santacana, Mireia , Hoffmeister, Michael , Murphy, Neil , Georgeson, Peter , Campbell, Peter T., Trinh, Quang M. , Berndt, Sonja I. , Brezina, Stefanie , Gruber, Stephen B. , Gallinger, Steven , Zaidi, Syed H., Harrison, Tabitha A. , Hudson, Thomas J , Moreno, Victor , Sun, Wei, Huang, Wen‐Yi , Wang, Xiaoliang , Lin, Yi, Peters, Ulrike , Hullar, Meredith A.J. , Phipps, Amanda I. , Ogino, Shuji

Mayo Clinic

International Journal of Surgery | May 6, 2026 | Volume: 112 | Issue: 5 | Pages: 11070-11085

10.1097/js9.0000000000003877 Get It

Background: Considering the pathophysiological importance of the intestine-passing microbiota, we hypothesized that the mutational and microbial profiles of colorectal cancer might gradually change along detailed anatomical locations and that these trends might differ by the age of diagnosis and the microsatellite instability (MSI) status. Methods: We assessed somatic mutations and selected bacterial species in colorectal carcinomas along the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, utilizing targeted sequencing data ( N = 5685) from the Genetics and Epidemiology of Colorectal Cancer Consortium and tissue microbial data ( N = 1389) from the Health Professionals Follow-up Study and Nurses’ Health Study. Results: There were decreasing trends from the cecum to rectum in the prevalence of gene mutations in the IGF/PI3K, receptor tyrosine kinase (RTK)/RAS, TGFB, and WNT signaling pathways (all P trend < 0.0001), as well as high levels of Bacteroides fragilis ( P trend < 0.0001) and high levels of Fusobacterium nucleatum ( P trend = 0.0029) (but not enterotoxigenic Bacteroides fragilis or pks+ Escherichia coli ). Conversely, TP53 pathway mutations showed an increasing cecum-to-rectum trend ( P trend < 0.0001). Similar to later-onset cases diagnosed at ages 50 years and older, in early-onset cases diagnosed under the age of 50 years, we found generally decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, TGFB, and WNT pathway mutations and an increasing cecum-to-rectum trend in TP53 pathway mutations. By contrast, the cecum-to-rectum prevalence-changing trends in IGF/PI3K, RTK/RAS, TGFB, and TP53 pathway mutations were present in non–MSI-high tumors but not in MSI-high tumors (all P interaction < 0.0052). Conclusion: Non–MSI-high colorectal cancers exhibited decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, and TGFB pathway mutations (and an increasing trend of TP53 pathway mutations), in contrast to MSI-high tumors that demonstrated no such trends. Our study highlights the importance of detailed colorectal subsite information combined with tumor molecular and microbial characteristics in colorectal cancer research.
Discovery of a CI-994 derivative as a dual modulator of class I HDACs and Wnt/β-catenin signaling for Alzheimer’s disease therapy
Lu, Wenyan, Lee, Eunmi, Wang, Ni , Bu, Guojun, Kanekiyo, Takahisa, Li, Yonghe, Jeevaratnam, Suren , Caulfield, Thomas R. , Lee, Eunmi , Bu, Guojun, Kanekiyo, Takahisa

Mayo Clinic

No container title available | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.30.721954 | PMID 42146614 Get It

Abstract Alzheimer’s disease (AD) is a multifactorial disease with mixed pathologies. Consequentially, drugs targeting multiple pathological processes may offer synergistic benefits. While histone deacetylase (HDAC) inhibitors have demonstrated efficacy in alleviating AD-related pathologies in animal models, the neuroprotective Wnt/β-catenin signaling pathway remains compromised in AD brain. CI-994 is a class I HDAC inhibitor containing N-(2-aminophenyl)-benzamide. Our recent studies indicate that CI-994 is also an activator of Wnt/β-catenin signaling by stabilizing Wnt co-receptor LRP6. We herein use CI-994 as a scaffold to develop novel potent dual modulators of class I HDACs and Wnt/β-catenin signaling for AD therapy. Our lead compound, W2A-28, selectively inhibits class I HDAC1, 2 and 3 with IC 50 values of 0.51 μM, 0.68 μM, and 0.22 μM, respectively, and shows no inhibitory activities on other HDACs. Furthermore, W2A-28 potently activates Wnt reporter activity with an EC 50 value of 1.61 μM in Wnt-3A-expressing HEK293 cells. As expected, activation of Wnt/β-catenin signaling by W2A-28 is associated with elevated LRP6 protein level. Importantly, W2A-28 displays excellent microsomal stability in both mouse and human liver microsomal stability assays, alongside high permeability and a lack of active efflux in MDR1-MDCKII models. Critically, W2A-28 treatment significantly enhances histone acetylation, activates Wnt/β-catenin signaling, and suppresses tau phosphorylation in AD patient-specific cerebral organoids carrying APOE ε4/ε4 or APOE ε3/ε4 with PSEN1 M146V mutation. Our findings position W2A-28 as a promising multi-target drug candidate for AD therapy.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
McGuirk, Joseph P. , Ghobadi, Armin , Bachier, Carlos, Shaughnessy, Paul , Awan, Farrukh T. , Maakaron, Joseph E., Bishop, Michael R. , Ho, P. Joy , Tam, Constantine S., Dickinson, Michael J., Darrah, Justin , Ross, Ainsley, Williams, Leah M., Pan, Chenyi , Stevens, William N., Serwer, Laura, Nguyen, Thao, Terrett, Jonathan, Kalaitzidis, Demetrios, Ma, Anna, Xu, Huansheng, Benton, Mark, Weaver, Annie, Cohen, S, Awan, Farrukh T , Dickinson, Michael , Waller, Edmund K , Murthy, Hemant S , Maziarz, Richard Thomas , Cheah, Chan Yoon , Bishop, Michael Russell , McGuirk, Joseph , Ghobadi, Armin , Maakaron, Joseph E. , Dickinson, Michael , Waller, Edmund K. , Murthy, Hemant S. , Williams, Leah M. , Serwer, Laura , Terrett, Jonathan A. , Weaver, Alana M., Beaussant, Sarah cohen , Cheah, Chan Y.

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020123 | PMID 42085626 Get It

This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric-antigen-receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1-4 (3-60 × 107 CAR T-cells; dose escalation, N=32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N=31). Primary endpoints in dose escalation and cohort expansion were incidence of dose-limiting toxicities and objective response rate, respectively. CTX110 was administered to 63 heavily pretreated patients: 59% primary refractory, 43% with ≥3 prior treatment lines. Among 57 patients whose first infusion was DL≥3, rates of objective and complete response (CR) were 65% and 39%, respectively. Among 22 patients achieving CR, 5 (23%) had ongoing CR at data cutoff, with 15-50 (median 34) months follow-up. The 2-infusion regimen appeared to prolong response duration compared to 1 infusion (hazard ratio 0.65). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in 54% and 13% of treated patients, respectively, including 2 grade ≥3 cases each. The most common grade ≥3 adverse events were neutropenia (59%), and anemia and thrombocytopenia (35% each). Serious adverse events occurred in 32% of treated patients, including CRS (14%), ICANS (8%), and febrile neutropenia (6%). In this r/r NHL population, CTX110 was well-tolerated, resulting in clinically meaningful responses at DL≥3, with a second infusion demonstrating evidence of further clinical benefit. This trial (NCT04035434) was registered at www.clinicaltrials.gov.